New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:19 EDTCGIXCGI announces collaborative study results on kidney cancer microarray test
Cancer Genetics announced the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required. Cancer Genetics is currently commercializing the test nationally by making it available as laboratory developed test. This study and final data were presented this week by Dr. Magi-Galluzzi of the Cleveland Clinic at a podium presentation at the 2014 United States & Canadian Academy of Pathology annual meeting in San Diego. These results provide additional evidence to support the clinical value of CGI's, unique, disease-focused, genomic tests.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:09 EDTCGIXCancer Genetics granted patent for FHACT
Subscribe for More Information
October 15, 2014
07:32 EDTCGIXRedChip Companies to hold a virtual conference
Subscribe for More Information
October 13, 2014
07:52 EDTCGIXCancer Genetics partners with Columbia University oncology researchers
Cancer Genetics has entered into a research collaboration with Columbia University's Azra Raza, MD, director of the MDS Center and assistant professor of medicine at Columbia University Medical Center, and Siddhartha Mukherjee, MD, PhD, assistant professor of medicine at CUMC, to identify more accurate diagnostic and prognostic markers for myelodysplastic syndromes, as well as novel therapies to target this class of bone marrow cancers. The ultimate goal of the collaboration is to develop personalized therapy for MDS patients and to enable accurate prediction of future treatment needs before patients become resistant to their current therapy or before their MDS progresses to the more aggressive acute myeloid leukemia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use